"Alkaline Phosphatase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
| Descriptor ID |
D000469
|
| MeSH Number(s) |
D08.811.277.352.650.035
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Alkaline Phosphatase".
Below are MeSH descriptors whose meaning is more specific than "Alkaline Phosphatase".
This graph shows the total number of publications written about "Alkaline Phosphatase" by people in this website by year, and whether "Alkaline Phosphatase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 2 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 6 | 7 |
| 2007 | 1 | 3 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 2 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alkaline Phosphatase" by people in Profiles.
-
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):783-794.
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):795-805.
-
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
-
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 08 01; 78(2):397-415.
-
Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. Pathology. 2022 Oct; 54(6):686-693.
-
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022 08; 77(2):353-364.
-
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
-
Laboratory-wide association study of survival with prostate cancer. Cancer. 2021 04 01; 127(7):1102-1113.
-
Case series and review of liver dysfunction in COVID-19 patients. Eur J Gastroenterol Hepatol. 2020 09; 32(9):1244-1250.
-
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2021 06; 19(6):1248-1257.